NCT02474914View on ClinicalTrials.gov

Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

NACompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Periampullary Carcinoma Resectable
Interventions
DRUG

Octreotide

Octreotide will be given after PD

DRUG

Placebo

Octreotide will NOT be given after PD

Trial Locations (1)

356111

Ayman El Nakeeb, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT02474914 - Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy | Biotech Hunter | Biotech Hunter